Literature DB >> 27896128

Overweight and obesity in PKU: The results from 8 centres in Europe and Turkey.

H Gokmen Ozel1, K Ahring2, A Bélanger-Quintana3, K Dokoupil4, A M Lammardo5, M Robert6, J C Rocha7, M F Almeida8, M van Rijn9, A MacDonald10.   

Abstract

INTRODUCTION: In PKU there is little data comparing the prevalence of overweight and obesity in different countries. The aim of this cross sectional study was to evaluate prevalence data from different PKU treatment centres in Europe and Turkey. SUBJECTS AND METHODS: In children, body mass index (BMI) and z scores and in adults BMI were calculated in 947 patients (783 children aged < 19 years; 164 adults aged ≥ 19 years) with PKU from centres in Europe and Turkey (Ankara, Birmingham, Brussels, Copenhagen, Groningen, Madrid, Munich and Porto).
RESULTS: In adults with PKU, 83% of centres (n = 5/6) had less overweight than the general populations but 83% (n = 5/6) had a higher rate of female obesity. In childhood, all centres reported obesity rates within or similar to local population ranges in boys but in 57% (n = 4/7) of centres a higher rate of obesity in girls. The percentage of overweight and obesity increased with age. DISCUSSION: In PKU, it is clear from a number of treatment centres that women and girls with PKU appear particularly vulnerable to excess weight gain and it is important that female weight gain is closely monitored and individual strategies introduced to prevent excess weight gain. Overall, in PKU there is a need to understand better the food patterns and activity levels of patients.

Entities:  

Keywords:  Obesity; Overweight; Phenylketonuria

Year:  2014        PMID: 27896128      PMCID: PMC5121346          DOI: 10.1016/j.ymgmr.2014.11.003

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


Introduction

In phenylketonuria (PKU) there is a suggestion that overweight and obesity is ‘equivalent to’ or more common than in the general population [1], [2], [3]. Low phenylalanine and high energy foods are encouraged in order to promote anabolism and to prevent protein insufficiency [4]. There is some speculation that this approach may promote obesity [1] but it requires further study. There are no evidence-based studies to indicate if overweight or obesity is related to the disorder itself, the low phenylalanine diet or patient lifestyle behaviour [4]. Considering that in PKU there are a lack of studies comparing prevalence of overweight and obesity between countries, the aim of this cross sectional study was to evaluate prevalence data from 8 different treatment centres in Europe and Turkey.

Subjects and methods

This was a retrospective, cross-sectional study comparing data on BMI (collected between 2005 and 2014), using a predefined set of questions for treated patients with PKU from one Turkish and 7 European centres. The centres providing data were from Belgium (Brussels), Denmark (Copenhagen), Germany (Munich), The Netherlands (Groningen), Portugal (Porto), Spain (Madrid), Turkey (Ankara) and the United Kingdom (UK) (Birmingham). One hundred and sixty four adults from 6 centres (Ankara, Brussels, Groningen, Madrid, Munich and Porto) and 783 children aged < 19 years from 7 centres (Ankara, Birmingham, Brussels, Copenhagen, Groningen, Madrid and Porto) were included (Table 1). This project was considered by the NHS Health Research Authority decision tool (www.hra-decisiontools.org.uk) as non-research and as such did not require ethical approval.
Table 1

Number of patients and patient demographics from 8 centres across Europe and Turkey all diagnosed by newborn screening.

PKU centresTotalTreatmentChildren (< 19 years)Adults
AnkaraData collected in 2008All patients born ≥ 1982411Low phe diet n = 411n = 397(219 boys, 178 girls)Age range: 1.7 months–17.9 years14(4 males, 10 females)Median age 22.9 years (range 19–26 years)
BirminghamData collected in 2014All children born ≥ 199685BH4 + low phe diet n = 7Low phe dietn = 78n = 85(46 boys, 39 girls)Age range: 1–17 yearsn/a
BrusselsData collected in 201262BH4 + low phe diet n = 12Low phe diet n = 50n = 40(20 boys, 20 girls)Age range: 1 year, 3 months–17 years, 11 months22(7 males, 15 females)Median age 19 years, 7 months
CopenhagenData collected in 2011All children born ≥ 199585Low phe diet n = 85n = 85(28 boys, 57 girls)Age range: 6–15 yearsn/a
GroningenData collected in 201178Low phe diet n = 78an = 45(23 boys, 22 girls)33(16 males, 17 females)
MadridData collected in 2012All patients born ≥ 197983BH4 only n = 11BH4 + low phe diet n = 8Low phe diet n = 64n = 49(21 males, 28 females)Age range: 1 year–< 19 years34(14 males, 20 females)
MunichData collected in 2005–2006All patients born ≥ 196732Low phe diet n = 32n/a32(12 males, 20 females)
PortoData collected in 2010–2011.All patients born ≥ 1982111Low phe diet n = 111n = 82(51 boys, 31 girls)Age range: 1 year–< 19 years29(10 males, 19 females)
Totals947947783164

25 patients started BH4 for only a short time pre-assessment of overweight/obesity.

Eligible patients with PKU were diagnosed by newborn screening, on dietary treatment, with or without BH4 (tetrahydrobiopterin, sapropterin dihydrochloride) therapy and with or without large neutral amino-acid (LNAA) supplements. Exclusion criteria included patients not on dietary treatment, on pre-conception diet, pregnant or late treated patients. The age, gender, height and body weight for all patients < 19 years of age were collected in routine hospital clinics. The WHO Anthro and AnthroPlus programmes, software programmes provided by the WHO, calculated BMI percentile and z-score. Overweight classification was as follows: for patients < 5 years: BMI z score ≥ 2 and < 3 SD, for patients 5–18 years: BMI z score ≥ 1 and < 2 SD. Obesity classification was for patients < 5 years: BMI z score ≥ 3 and for patients 5–18 years: BMI z score ≥ 2 SD [5], [6], [7], [8]. Percentages of overweight/obesity and obesity were calculated respectively from BMI z scores and compared with local general population ranges [9]. For adult PKU patients (≥ 19 years), BMI was calculated as weight (kg) / height (m2), and classified into BMI categories according to the WHO classification; overweight (≥ 25.0–29.9 kg/m2) and obesity (≥ 30.0 kg/m2) [10]. Subsequently, percentages of overweight/obesity and obesity were calculated.

Results

Adults (Table 2)

The majority of centres (83%; n = 5 of 6) had less overweight in patients with PKU, with obesity rates being the same or less in 4 of 6 (67%) centres than the respective general populations. In 5 of 6 (83%) centres there was a higher rate of obesity in females than males and in 4 centres this was higher than the respective general population. In contrast, only in Groningen and Munich were there more obese males with PKU than the general population.

Children (Table 3)

In boys in Ankara, Birmingham, and Porto there were less overweight and obesity than the respective ranges in the general populations. Although boys in Brussels, Copenhagen, Groningen and older boys in Madrid had a higher rate of combined overweight/obesity, they had a lower rate of obesity only than the general population ranges. In girls there was a higher rate of combined overweight/obesity in Brussels, and Copenhagen and more obesity only in Ankara, Birmingham, Copenhagen and Groningen than the general population ranges. In Brussels, Madrid and Porto girls, there was less obesity.

Discussion

This is the first multi-centre European and Turkish cross sectional study in 947 patients with PKU to report the prevalence of overweight and obesity. In adults, the majority of centres reported similar or lower rates of obesity to their general populations [10]. In children although there is less or similar rates of obesity in boys to the local general population, in girls there is a trend for a higher rate of obesity, as previously reported [2], [3]. It is unknown if body composition studies would reflect the same trend and this deserves further study [11]. In parallel to the respective general populations [9], [10], the percentage of overweight increased with age. In order to avoid using different criteria to assess defining overweight and obesity and to facilitate comparisons between different countries and populations, in this survey the WHO BMI z scores were used to assess overweight and obesity in children and the body mass index (weight / height2) for the adult population. Overall, despite similar PKU treatment approaches, the prevalence of overweight and obesity did vary between treatment centres, and it commonly followed respective national trends. Blood phenylalanine control of PKU patients from this group of PKU centres, except for Porto, has been published previously [12]. Energy and protein intakes were not reported in this audit but commonly overweight and obesity result from an eclectic combination of genetic, environmental, dietary and social factors. Although in non-PKU individuals, associated non-dietary factors include maternal overweight, high birth weight and smoking in pregnancy, there is little data reported in PKU for any of these factors [4]. In conclusion, although the prevalence of overweight and obesity varied widely between countries it was mainly similar or even less than the respective general populations for adults and boys. Women and girls with PKU appear particularly vulnerable to excess weight gain and it is important that female weight gain is targeted and closely monitored from an early age with individual strategies introduced to avoid and control excess weight gain. More research is needed to identify the main risk factors associated with overweight and obesity in females with PKU. In general, there is a need to better understand the food patterns, energy and nutrient intakes and the physical activity of patients with PKU.

Authors' roles

All authors were involved in data collection, interpretation of data, writing and critical revision of the paper for important intellectual content and final approval of the version to be published.

Source of funding

There has been no funding for this study.

Conflict of interest

Hulya Gokmen Ozel, Kirsten Ahring, Katharina Dokoupil, Anna Maria Lammardo, Martine Robert, and Julio C Rocha are members of the European Nutrition Expert Panel which is supported by Merck Serono. Anita MacDonald has received research funding and honoraria from Nutricia, Vitaflo International and Merck Serono. She is a member of the European Nutrition Expert Panel (Merck Serono International), member of Sapropterin Advisory Board (Merck Serono international), and member of the Advisory Board Element (Danone-Nutricia). Margreet van Rijn is a member of the European Nutrition Expert Panel (Merck Serono), a consultant of Danone Research and Development, a member of the Advisory Board Element (Danone-Nutricia), and has received financial research support from Nutricia Netherlands and honoraria for lecturing and guideline development (Orphan Europe, SSIF). Amaya Bélanger-Quintana is a member of the European Nutrition Expert Panel (Merck Serono) and member of Sapropterin Advisory Board (Merck Serono).
Table 2

Overweight and obesity percentages in adults with PKU compared with national general population (OECD i library, updated 2013) and gender differences for 6 centres.

PKU centresPKU population % overweight/obeseBMI ≥ 25.0 kg/m2General population % overweight/obeseBMI ≥ 25.0 kg/m2PKU population % obesityBMI ≥ 30 kg/m2General population % obesityBMI ≥ 30 kg/m2Gender differences
Overweight
Obesity
Male%Female%Male%Female%
Ankara28.433.014.316.925.020.0020.0
Brussels27.333.14.513.814.333.306.7
Groningen15.236.824.211.419.024.019.018.0
Madrid42.037.616.016.042.040.07.025.0
Munich34.436.718.714.733.335.016.720
Porto24.136.210.315.430.021.110.010.5
Table 3

Overweight and obesity percentages in children with PKU compared with national general population (Ng et al. [9]) for 7 centres.

PKU centresAge of children with PKU% overweight (includes overweight and obesity) in PKU% obesity in PKUBoys (PKU)
Girls (PKU)
Data from global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: Ng et al. [9]
Boys
Girls
Overweight (includes overweight and obesity)ObesityOverweight (includes overweight and obesityObesityOverweight (includes overweight and obesityObesityOverweight (includes overweight and obesityObesity
Ankara1.7–17.9 yearsmedian age 4.6 years(n = 397)19.8%9.8%18.7%7.8%21.3%12.3%20.4 (17.5–23.6)7.1 (5.7–8.7)19.8 (16.6–23)5.7 (4.5–7)
Birmingham1–3 years (n = 12)4–11 years (n = 45)≥ 12 years–18 years (n = 28)8%20%43%0%8.9%11%21.7%6.5%31%10.3%26.1 (23.8–28.5)7.4 (6.5–8.5)29.2 (26.8–31.9)8.1 (7.0–9.3)
Brussels1–8 yearsmedian age 7.1 years32.5%2.5%40%5%25%0%20.5 (17.7–23.6)4.6 (3.7–5.5)18.8 (16.0–21.8)4.2 (3.3–5.1)
Copenhagen6–10 years (n = 49)11–15 years (n = 36)29%30%6%8%33%27%7%0%26%35%9%13%19.7 (16.8–23.1)8.7 (7.1–10.7)19.4 (15.8–23.2)5.9 (4.7–7.5)
Groningen4–10 years (n = 28)11–18 years (n = 17)25%45%4%17%45%0%17%17%18.3 (15.7–21.3)4.1 (3.4–5)16.1 (13.4–18.9)3.8 (3–4.7)
Madrid≤ 10 years (n = 30)10–18 years (n = 19)3%29%3%0%0%37%6%0%0%22%0%0%27.6 (23.9–31.2)8.4 (6.7–10.2)23.8 (20.2–27.4)7.6 (6.0–9.3)
Porto< 5 years (n = 9)5–< 19 years (n = 73)0%26%0%8.2%0%22.7%0%9.1%0%31%0%6.9%28.7 (24.9–31.8)8.9 (7.4–10.9)27.1 (23.4–31.4)10.6 (8.5–12.9)
  10 in total

1.  WHO Child Growth Standards based on length/height, weight and age.

Authors: 
Journal:  Acta Paediatr Suppl       Date:  2006-04

2.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

Review 3.  Is overweight an issue in phenylketonuria?

Authors:  Júlio C Rocha; Anita MacDonald; Friedrich Trefz
Journal:  Mol Genet Metab       Date:  2013-08-31       Impact factor: 4.797

4.  Blood phenylalanine control in phenylketonuria: a survey of 10 European centres.

Authors:  K Ahring; A Bélanger-Quintana; K Dokoupil; H Gokmen-Ozel; A M Lammardo; A MacDonald; K Motzfeldt; M Nowacka; M Robert; M van Rijn
Journal:  Eur J Clin Nutr       Date:  2010-12-01       Impact factor: 4.016

5.  High prevalence of overweight and obesity in females with phenylketonuria.

Authors:  Lindsay C Burrage; Judy McConnell; Rebecca Haesler; Mary Ann O'Riordan; V Reid Sutton; Douglas S Kerr; Shawn E McCandless
Journal:  Mol Genet Metab       Date:  2012-07-16       Impact factor: 4.797

6.  Development of a WHO growth reference for school-aged children and adolescents.

Authors:  Mercedes de Onis; Adelheid W Onyango; Elaine Borghi; Amani Siyam; Chizuru Nishida; Jonathan Siekmann
Journal:  Bull World Health Organ       Date:  2007-09       Impact factor: 9.408

7.  Body mass index in adult patients with diet-treated phenylketonuria.

Authors:  L V Robertson; N McStravick; S Ripley; E Weetch; S Donald; S Adam; A Micciche; S Boocock; A MacDonald
Journal:  J Hum Nutr Diet       Date:  2013-04-03       Impact factor: 3.089

8.  Dietary treatment in phenylketonuria does not lead to increased risk of obesity or metabolic syndrome.

Authors:  Júlio C Rocha; Francjan J van Spronsen; Manuela F Almeida; Gabriela Soares; Dulce Quelhas; Elisabete Ramos; João T Guimarães; Nuno Borges
Journal:  Mol Genet Metab       Date:  2012-10-16       Impact factor: 4.797

9.  Whole body composition analysis by the BodPod air-displacement plethysmography method in children with phenylketonuria shows a higher body fat percentage.

Authors:  Monique Albersen; Marjolein Bonthuis; Nicole M de Roos; Dorine A M van den Hurk; Ems Carbasius Weber; Margriet M W B Hendriks; Monique G M de Sain-van der Velden; Tom J de Koning; Gepke Visser
Journal:  J Inherit Metab Dis       Date:  2010-06-24       Impact factor: 4.982

10.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:  Marie Ng; Tom Fleming; Margaret Robinson; Blake Thomson; Nicholas Graetz; Christopher Margono; Erin C Mullany; Stan Biryukov; Cristiana Abbafati; Semaw Ferede Abera; Jerry P Abraham; Niveen M E Abu-Rmeileh; Tom Achoki; Fadia S AlBuhairan; Zewdie A Alemu; Rafael Alfonso; Mohammed K Ali; Raghib Ali; Nelson Alvis Guzman; Walid Ammar; Palwasha Anwari; Amitava Banerjee; Simon Barquera; Sanjay Basu; Derrick A Bennett; Zulfiqar Bhutta; Jed Blore; Norberto Cabral; Ismael Campos Nonato; Jung-Chen Chang; Rajiv Chowdhury; Karen J Courville; Michael H Criqui; David K Cundiff; Kaustubh C Dabhadkar; Lalit Dandona; Adrian Davis; Anand Dayama; Samath D Dharmaratne; Eric L Ding; Adnan M Durrani; Alireza Esteghamati; Farshad Farzadfar; Derek F J Fay; Valery L Feigin; Abraham Flaxman; Mohammad H Forouzanfar; Atsushi Goto; Mark A Green; Rajeev Gupta; Nima Hafezi-Nejad; Graeme J Hankey; Heather C Harewood; Rasmus Havmoeller; Simon Hay; Lucia Hernandez; Abdullatif Husseini; Bulat T Idrisov; Nayu Ikeda; Farhad Islami; Eiman Jahangir; Simerjot K Jassal; Sun Ha Jee; Mona Jeffreys; Jost B Jonas; Edmond K Kabagambe; Shams Eldin Ali Hassan Khalifa; Andre Pascal Kengne; Yousef Saleh Khader; Young-Ho Khang; Daniel Kim; Ruth W Kimokoti; Jonas M Kinge; Yoshihiro Kokubo; Soewarta Kosen; Gene Kwan; Taavi Lai; Mall Leinsalu; Yichong Li; Xiaofeng Liang; Shiwei Liu; Giancarlo Logroscino; Paulo A Lotufo; Yuan Lu; Jixiang Ma; Nana Kwaku Mainoo; George A Mensah; Tony R Merriman; Ali H Mokdad; Joanna Moschandreas; Mohsen Naghavi; Aliya Naheed; Devina Nand; K M Venkat Narayan; Erica Leigh Nelson; Marian L Neuhouser; Muhammad Imran Nisar; Takayoshi Ohkubo; Samuel O Oti; Andrea Pedroza; Dorairaj Prabhakaran; Nobhojit Roy; Uchechukwu Sampson; Hyeyoung Seo; Sadaf G Sepanlou; Kenji Shibuya; Rahman Shiri; Ivy Shiue; Gitanjali M Singh; Jasvinder A Singh; Vegard Skirbekk; Nicolas J C Stapelberg; Lela Sturua; Bryan L Sykes; Martin Tobias; Bach X Tran; Leonardo Trasande; Hideaki Toyoshima; Steven van de Vijver; Tommi J Vasankari; J Lennert Veerman; Gustavo Velasquez-Melendez; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Theo Vos; Claire Wang; XiaoRong Wang; Elisabete Weiderpass; Andrea Werdecker; Jonathan L Wright; Y Claire Yang; Hiroshi Yatsuya; Jihyun Yoon; Seok-Jun Yoon; Yong Zhao; Maigeng Zhou; Shankuan Zhu; Alan D Lopez; Christopher J L Murray; Emmanuela Gakidou
Journal:  Lancet       Date:  2014-05-29       Impact factor: 79.321

  10 in total
  9 in total

Review 1.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

2.  The influence of parental food preference and neophobia on children with phenylketonuria (PKU).

Authors:  Sharon Evans; Anne Daly; Satnam Chahal; Catherine Ashmore; John MacDonald; Anita MacDonald
Journal:  Mol Genet Metab Rep       Date:  2017-10-31

3.  Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.

Authors:  María Luz Couce; Paula Sánchez-Pintos; Luís Aldámiz-Echevarría; Isidro Vitoria; Victor Navas; Elena Martín-Hernández; Camila García-Volpe; Guillem Pintos; Luis Peña-Quintana; Tomás Hernández; David Gil; Félix Sánchez-Valverde; María Bueno; Iria Roca; Encarna López-Ruzafa; Carmen Díaz-Fernández
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

4.  Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data.

Authors:  K F Trefz; A C Muntau; K M Kohlscheen; J Altevers; C Jacob; S Braun; W Greiner; A Jha; M Jain; I Alvarez; P Lane; C Schröder; F Rutsch
Journal:  Orphanet J Rare Dis       Date:  2019-07-22       Impact factor: 4.123

5.  Body fat percentage in adolescents with phenylketonuria and associated factors.

Authors:  Giovanna Caliman Camatta; Viviane de Cássia Kanufre; Michelle Rosa Andrade Alves; Rosângelis Del Lama Soares; Rocksane de Carvalho Norton; Marcos José Burle de Aguiar; Ana Lúcia Pimenta Starling
Journal:  Mol Genet Metab Rep       Date:  2020-05-12

6.  Health economic burden of patients with phenylketonuria (PKU) - A retrospective study of German health insurance claims data.

Authors:  Friedrich Trefz; Ania C Muntau; Kim M Schneider; Julia Altevers; Christian Jacob; Sebastian Braun; Wolfgang Greiner; Ashok Jha; Mohit Jain; Ignacio Alvarez; Paul Lane; Claudia Zeiss; Frank Rutsch
Journal:  Mol Genet Metab Rep       Date:  2021-05-13

7.  OVERWEIGHT AND ASSOCIATED FACTORS IN CHILDREN AND ADOLESCENTS WITH PHENYLKETONURIA: A SYSTEMATIC REVIEW.

Authors:  Berilany Dos Santos Sena; Maria Izabel Siqueira de Andrade; Ana Paula Ferreira da Silva; Keila Fernandes Dourado; Andressa Laís Ferreira Silva
Journal:  Rev Paul Pediatr       Date:  2020-03-09

8.  Dietetic Management of Adults with Phenylketonuria (PKU) in the UK: A Care Consensus Document.

Authors:  Louise Robertson; Sarah Adam; Charlotte Ellerton; Suzanne Ford; Melanie Hill; Gemma Randles; Alison Woodall; Carla Young; Anita MacDonald
Journal:  Nutrients       Date:  2022-01-28       Impact factor: 5.717

9.  Overweight/obesity in adolescents with phenylketonuria: protective and predisposing factors.

Authors:  Adriana Márcia Silveira; Poliane Lopes Lima; Michelle Rosa Andrade Alves; Rosângelis Del Lama Soares; Viviane de Cássia Kanufre; Valéria de Melo Rodrigues; Ana Lúcia Pimenta Starling; Rocksane de Carvalho Norton; Marcos José Burle de Aguiar
Journal:  J Pediatr (Rio J)       Date:  2021-06-16       Impact factor: 2.990

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.